Cinnarizine

Cinnarizine is an orally active, effective and selective inhibitor of L-type calcium channel Cav1.3 with an IC50 of 1.5 μM (in vestibular hair cells) . Cinnarizine can cross the blood-brain barrier and regulate calcium homeostasis and dopamine neurotransmission. Cinnarizine inhibits the influx of calcium ions into smooth muscle cells by blocking L-type calcium channels, thereby relaxing vascular smooth muscle, improving cerebral circulation and reducing blood viscosity, while antagonizing dopamine receptors. Cinnarizine can be used in the study of vestibular vertigo, Meniere's disease and cerebrovascular diseases[1][2][3][4][5].

Product Specifications

CAS Number

[298-57-7]

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335, H410

Target

Calcium Channel; Histamine Receptor

Type

Reference compound

Related Pathways

GPCR/G Protein; Immunology/Inflammation; Membrane Transporter/Ion Channel; Neuronal Signaling

Applications

COVID-19-immunoregulation

Field of Research

Cardiovascular Disease; Endocrinology

Assay Protocol

https://www.medchemexpress.com/Cinnarizine.html

Purity

99.63

Solubility

DMSO : 7.14 mg/mL (ultrasonic)

Smiles

N1(C(C2=CC=CC=C2)C3=CC=CC=C3)CCN(C/C=C/C4=CC=CC=C4)CC1

Molecular Formula

C26H28N2

Molecular Weight

368.51

Precautions

H302, H315, H319, H335, H410

References & Citations

[1]Arab SF, et al. Inhibition of voltage-gated calcium currents in type II vestibular hair cells by cinnarizine. Naunyn Schmiedebergs Arch Pharmacol. 2004 Jun;369 (6) :570-5.|[2]Düwel P, et al. Effects of cinnarizine on calcium and pressure-dependent potassium currents in guinea pig vestibular hair cells. Naunyn Schmiedebergs Arch Pharmacol. 2005 Jun;371 (6) :441-8.|[3]Ng E, et al. Evaluation of Aldosterone Suppression by Cinnarizine, a Putative Cav1.3 Inhibitor. J Clin Endocrinol Metab. 2025 Feb 10:dgaf081.|[4]Serrano A, et al. Effects of cinnarizine, a calcium antagonist that produces human parkinsonism, in parkin knock out mice. Neuropharmacology. 2005 Aug;49 (2) :208-19.|[5]Li BQ, et al. Effect of route of administration on the pharmacokinetics and toxicokinetics of cinnarizine in dogs. Eur J Pharm Sci. 2010 Jun 14;40 (3) :197-201.